The microbial composition and functional roles of different kombucha products in Singapore

Suet Li Hooi[1,*], Jacky Dwiyanto[2], Kai Yee Toh[1], Gwendoline Tan[1], Chun Wie Chong[1,5], Jonathan Wei Jie Lee[1,3,4], Jeremy Lim[1,*]

[1]AMILI Pte Ltd, 89 Science Park Drive #03-09, The Rutherford, Lobby C, Singapore Science Park 1, Singapore 118261

[2]Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia

[3]Division of Gastroenterology & Hepatology, National University Hospital, Singapore

[4]Yong Loo Lin School of Medicine, National University of Singapore, Singapore

[5]School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia

*Corresponding author

1) Suet Li Hooi

Email: suetli.hooi@amili.asia

2) Jeremy Lim

Email: jeremy.lim@amili.asia

Abstract

Kombucha is a fermented tea traditionally known for its health-enhancing properties owing to the bioactive compounds generated by acetic acid bacteria (AAB) and lactic acid bacteria (LAB). We compared the distribution of AAB and LAB and their functional pathways across nine commercial kombucha products in Singapore using shotgun metagenomic sequencing. A high prevalence of *Komagataeibacter* species including *Komagataeibacter saccharivorans* (82.93% in B), *Komagataeibacter xylinus* (93.38% in D) and *Komagataeibacter rhaeticus* (92.20% and 30.62% in G and I) was detected in AAB-dominant kombucha. LAB-dominant kombucha was largely represented by *Bacillus coagulans* (~99% in E and F) and *Lactobacillus nagelii* (~60% in H). Despite differences in bacterial composition, both LAB-and AAB-dominant kombucha harbour pathways involved in the biosynthesis of short-chain fatty acids (SCFAs), amino and organic acids and vitamin B12. "Fatty acid and beta-oxidation II (peroxisome)" and "fatty acid and beta-oxidation I" were detected in the LAB but not the AAB-dominant kombucha.

Keywords: Bioactive compounds, functional pathways, shotgun metagenomic sequencing, *Komagataeibacter*, *Bacillus coagulans*, SCFA, kombucha, microbiome, microbiota

Introduction

Kombucha is a traditionally fermented drink produced from the fermentation of sweetened green, black or oolong tea by the symbiotic culture of bacteria and yeast (SCOBY) [1,2]. This traditional beverage has been widely consumed worldwide over the last decade due to its purported health benefits. For instance, regular consumption of kombucha is believed to reduce blood pressure, aid in weight loss, improve immunity, facilitate digestion, prevent the development of metabolic and gastrointestinal diseases as well as cancer

[1,3]. These positive health effects of kombucha are mainly attributed to the unique microbial consortium

and the bioactive compounds these microbes produce during the fermentation process [4].

The SCOBY in kombucha is primarily made up of yeast and a large proportion of bacteria called acetic

acid bacteria (AAB). AAB are Gram-negative obligate aerobes (which strictly require oxygen to survive)

belonging to the *Acetobacteraceae* family. They can grow optimally at temperatures of approximately 25

to 30 °C and a pH of 5.0 to 6.5 [5,6]. The most prevalent AAB in kombucha are the species of the genera

Komagataeibacter, *Gluconobacter, Acetobacter* and *Gluconacetobacter* [6]. Common AAB species found

in commercial kombucha are *Komagataeibacter xylinus*, *Komagataeibacter saccharivorans*, *Acetobacter*

xylinum and *Gluconobacter oxydans* [3,7,8]. These bacteria produce acetic acid and cellulose through the

fermentation process. The metabolic products, in-turn confer various health-promoting properties such as

antimicrobial activities and the prevention of metabolic diseases like diabetes and obesity by decreasing

intestinal glucose absorption and converting glucose into cellulose [2,9].

Lactic acid bacteria (LAB) are less frequently detected in kombucha. When present, LAB are usually found

in relatively low abundances [6,7,8]. However, LAB such as *Bacillus coagulans* and *Lactobacillus* species

are often added in commercial kombucha fermentation to enhance the probiotic potential of the beverage

[8,10]. LAB are Gram-positive, facultative anaerobic bacteria (can survive in the presence or absence of

oxygen) belonging to the *Firmicutes* phylum, which grows optimally at temperatures between 25 to 40°C

and a pH of 4.0 to 6.0. LAB can be categorised into either homofermenters or heterofermenters [11,12].

Lactobacillus, Lactococcus and *Streptococcus* species are among the most common homofermenters which

utilise glucose to produce lactic acid as the primary end-product of glycolysis. Meanwhile, heterofermenters

such as *Leuconostoc* and *Weisella* spp. generate lactic acid, carbon dioxide and ethanol via the pentose

phosphate pathway [6,11,12]. Similar to AAB, the metabolites produced by LAB facilitate digestion,

prevent infections and exert immunomodulation properties [11,12].

The different preparation and brewing processes have resulted in variable microbial composition across

kombucha. In this study, we profiled the microbial composition and functional pathways of nine

commercial kombucha products in Singapore using shotgun metagenomics sequencing. We further

compared the microbial and functional differences between the AAB-and LAB-dominant.

Methods

Sample procurement and processing

87   Nine kombucha products were obtained from commercial supermarkets in Singapore. Each product was

88   brewed according to the manufacturer's instruction. The products were stored at 4°C, with a shelf-life of up

89   to 12 months. Unpasteurised kombucha products were procured and sent to the laboratory for subsequent

90   steps on the same day.

DNA extraction and shotgun metagenomic sequencing

A total of 300 to 350mL of each product was centrifuged at 6000$\times$g. The resulting supernatant was removed,

and the pellet was stored at -80°C. The DNA from the frozen pellet was extracted using QIAamp

PowerFecal Pro DNA kit according to the manufacturer's protocol and quantified using Qubit 4

fluorometer. DNA sequencing was performed using Illumina NovaSeq with 2$\times$150bp paired-end

configuration and a read depth of 20 million paired-end reads. The raw sequence reads were processed

using BioBakery3 workflows [13]. Read-level quality control was conducted using KneadData v0.11.0 with

default settings [13]. Taxonomy annotations were performed using MetaPhlan version 3.0 which uses clade-

specific markers to identify microbial species and their relative abundances. Meanwhile, functional

pathways annotations were conducted using HUMAnN version 3.0 based on the MetaCyc pathway database

[13].

Data analysis

Species and pathway abundances were analysed using phyloseq R package version 1.36.0 [14]. Species and

functional pathways with <10% and <0.01% relative abundances respectively were discarded using

genefilter_sample and prune_taxa functions from the phyloseq R package version 1.36.0 [14]. The bar plots

were generated using ggplot2 R package version 3.3.5 whereas the heatmap was generated using

ComplexHeatmap R package version 2.13.1 [15,16]. The products were categorised as AAB- or LAB-

dominant if the relative abundances of either AAB or LAB species reached more than 30%. Non-AAB- and

LAB-dominant products (relative abundances of AAB, LAB or other species (<30%) were categorised as

"others".

Results

All nine products were unpasteurised, and most ($n = 5$) used either SCOBY or acidifier ($n = 2$) as the starter

culture. *Bacillus coagulans* which was added in E and F and was detected in our analysis with relative

abundances of almost 100% (99.95% and 99.98% respectively). However, the species of *Lactobacillus*,

Acetobacter, *Gluconobacter* and *Saccharomyces,* which claimed to be added in products D and G by the

respective manufacturers were either below detection limit or present in low abundance (2.06% of

Saccharomyces cerevisiae in G) **(Table 1** and **Fig 1a).**

Table 1. Commercial claims and microbiome profiles of the kombucha products ($n = 9$) included in

this study.

Starter culture	Product	Type of dominant bacteria present	Probiotics added*	Number of microbial species	Number of functional pathways	Average pathways per species
Acidifier	A	Others	None	27	314	11.63
Acidifier	B	AAB	None	4	130	32.50
SCOBY	C	Others	None	96	390	4.06
SCOBY	D	AAB	Yeast and *Lactobacillus* species	4	148	37
Unknown	E	LAB	*Bacillus coagulans*	3	117	58.5
Unknown	F	LAB	*Bacillus coagulans*	2	137	45.67
SCOBY	G	AAB	Yeast of the *Saccharomyces* genus and bacteria from *Acetobacter* and *Gluconobacter* species	3	97	32.33
SCOBY	H	LAB	None	7	192	27.43
SCOBY	I	AAB	None	6	142	23.67

123 * As claimed by the kombucha manufacturer

Overall, 141 microbial species were detected across all nine products. Eighty-one species remained after filtering for low species abundance (<10%) **(Fig 1a)**. Product C had the highest species diversity, followed by product A and the remaining products contained less than ten species **(Table 1)**.

Fig 1a. Heatmap of microbial species. The heatmap of 81 microbial species detected across the nine

kombucha products after filtering for species with >10% relative abundance.

The classification of species from AAB and LAB was based on the definition set by previous literature

[5,11]. Four out of the nine products were predominated by AAB, notably the species from the

Komagataeibacter genus (relative abundance > 30%). These four products, B, D, G and I were

predominated by *Komagataeibacter saccharivorans* (B), *Komagataeibacter xylinus* (D) and

Komagataeibacter rhaeticus (G and I) with relative abundances of 82.93%, 93.38%, 92.20% and 30.62%,

respectively. LAB-dominant products were E, F and H, with relative abundances of *Bacillus coagulans* in

E and F at 99.95% and 99.98%, respectively and *Lactobacillus nagelli* in H at 64.12% **(Fig 1a)**.

After removing functional pathways with <0.01% relative abundance, 59 out of 433 pathways remained.

The top five most abundant functional pathways were the pentose phosphate pathway (non-oxidative

branch), aerobic respiration I (cytochrome c), aerobic respiration II (cytochrome c) (yeast), guanosine

deoxyribonucleotides de novo biosynthesis II and adenosine deoxyribonucleotides de novo biosynthesis II

(Fig 2a).

Fig 2a. Functional pathways. The top 59 functional pathways after removing those with less than 0.01%

relative abundance (the relative abundances were normalised to 100% in this figure) across all the nine

kombucha products.

Fig 2b. Species contribution. The relative abundances of the top 20 functional pathways contributed by

three categories of microbes; AAB, LAB and others. Unclassified species contributing to the pathways

across the nine products were excluded.

Of the 59 pathways, we further selected 20 that are involved in the production of beneficial metabolites.

AAB was found to harbour 15 out of the 20 selected pathways (75%), while 11 pathways (55%) were

detected in LAB. Notably, 2 out of 20 functional pathways (10%) were exclusively contributed by LAB

and "others". These pathways were "fatty acid and beta-oxidation II (peroxisome)" and "fatty acid and beta-

oxidation I". Meanwhile, 6 out of 20 (30%) were exclusively contributed by AAB and "others" **(Fig 2b)**.

Discussion

The growing popularity of kombucha in the last decade has motivated many beverage companies to

introduce various new fermentation strategies, starter cultures and additional flavours, which results in

unique microbial and metabolite profiles among different kombucha products. Notably, the bacterial

composition in kombucha is comprised mainly of AAB and LAB. These bacteria play an essential role in

producing bioactive compounds, thereby contributing to the pro-health effects of kombucha [3,6]. In this

study, we analysed nine commercial kombucha products in Singapore and compared the composition of

AAB and LAB and their functional potentials. Shotgun metagenomics sequencing revealed that the studied

kombucha can be largely classified into three categories, namely the AAB- dominant (B, D, G and I), LAB-

dominant (E, F and H) and others (A and C).

Consistent with other parallel kombucha studies, *Komagateibacter saccharivorans*, *Komagataeibacter*

xylinus and *Komagataeibacter rhaeticus* are the most abundant and prevalent *Komagataeibacter* species

found in the AAB-dominant products [8,17,18]. Interestingly, the high prevalence of *Komagataeibacter*

spp. was found across geographically distant locations (e.g. Australia, China, Turkey and USA), suggesting

a degree of standardisation in the kombucha preparation [7-8,17-19]. The species of *Komagataeibacter* are

reported to exhibit efficient glucose-metabolising activities (e.g. high glucose conversion rate to cellulose)

which have a putative role in preventing the onset of metabolic diseases such as type-2 diabetes and obesity

[9,18].

Our study found the three LAB-dominant products (E, F and H) were predominated by *Bacillus coagulans*

(~99% relative abundances in E and F) and *Lactobacillus nagelii* (64.12% relative abundance in H). Our

finding was consistent with the previous studies conducted in America which also detected the

predominance of these LAB species in their tested kombucha samples [7,8]. *B. coagulans* are often added

to food products not only due to their numerous probiotic characteristics but also their high tolerance to

extreme environments such as high temperature and acidity. *B. coagulans* possess a wide range of probiotic

attributes such as promoting intestinal digestion, modulating the immune system, preventing pathogenic

bacteria colonization, and alleviating certain diseases and gastrointestinal tract (GIT) disorders such as

irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and colorectal cancer [8,20,21]. The

predominance of *B. coagulans* in these products was consistent with the claims made by the product

manufacturer. Nonetheless, some probiotic species labelled by the manufacturers were not detectable, likely

due to the detection limit of our sequencing approach, or the unfavourable storage conditions. *Lactobacillus*

nagelii, a common *Lactobacillus* species found in kombucha predominated product H. The species of

Lactobacillus (LAB) are known to enhance the health-promoting properties of kombucha and widely

regarded as probiotics as they can produce short-chain fatty acids (SCFAs), amines, bacteriocins and

vitamins involved in antimicrobial and antioxidant activities as well as gut health maintenance, among

others [10,12].

To evaluate the health benefits of kombucha, we analysed the functional potential of the microbes across

the nine products. The top five out of 59 functional pathways detected were related to sugar metabolism

(pentose phosphate pathway (non-oxidative branch), aerobic respiration I (cytochrome c), aerobic

respiration II (cytochrome c) (yeast)) and the production of purines (guanosine deoxyribonucleotides de

novo biosynthesis II and adenosine deoxyribonucleotides de novo biosynthesis II). Some of the products of

these pathways such as ribose-5-phosphate sugar, nicotinamide adenine dinucleotide phosphate (NADPH),

adenosine triphosphate (ATP) and purines act as essential growth factors and energy sources for the

microbes to synthesise bioactive compounds in the kombucha culture [1].

We further selected 20 functional pathways including SCFAs production, biosynthesis of precursors for B

vitamins, amino acids and organic acids [1,4,8]. We noted that functional pathways such as "fatty acid and

beta-oxidation II (peroxisome)" and "fatty acid and beta-oxidation I" were only contributed by LAB but

not AAB. These pathways metabolised fatty acids to produce acetyl-CoA in an anaerobic condition. Acetyl-

CoA is a precursor for the biosynthesis of acetate, one of the common SCFAs that play an essential role in

maintaining gut health, immune homeostasis and preventing disease development [22]. LAB, which are

facultative anaerobes may utilize these pathways to generate SCFAs when oxygen level is depleted during

kombucha fermentation, unlike AAB, which requires oxygen to grow [6,20,23-24].

In comparison, AAB contributed 20% more pathways involved in sugar metabolism, respiration,

biosynthesis of amino acids and B vitamins than LAB. For instance, superpathway of aromatic amino acid

biosynthesis, superpathway of acetyl-CoA biosynthesis, chorismate biosynthesis I, aerobic respiration II

(cytochrome c) (yeast), aerobic respiration I (cytochrome c) and biosynthesis of adenosylcobalamin

(vitamin B12) were among the pathways found in AAB but absent in LAB. Meanwhile, lower abundances

of species from the "others" group contributed to the 20 selected pathways as compared to AAB and LAB.

This could suggest that AAB and LAB possess greater capability in producing beneficial metabolites as

compared to non-AAB and -LAB species.

Nevertheless, the exact metabolite composition in kombucha would require further targeted chemical
assays. One of the limitations of our study is the small sample size, contributed mainly by the relatively
limited number of kombucha brands in Singapore. Future work to assess the stability of kombucha
microbiome over different production batches is warranted to understand the consistency of microbial and
chemical compositions in kombucha. Clinical studies including *in vivo* tests and bioavailability assessments
are indispensable to provide clinical evidence of kombucha's biological activities in humans, thereby
confirming the positive health implications of this popular beverage.

Conclusion

Komagataeibacter species, namely *Komagateibacter saccharivorans*, *Komagataeibacter xylinus* and
Komagataeibacter rhaeticus were the most prevalent and dominant bacteria present in AAB-dominant
products (B, D, G and I) whereas *Bacillus coagulans* and *Lactobacillus nagelii* were the dominant species
detected in LAB-dominant products (E, F and H). Although the functional pathways contributed by AAB
differed from those contributed by LAB, both categories of bacteria can generate specific organic acids,
amino acids, vitamin B compounds and SCFAs with health-enhancing properties in kombucha. Future work
to characterise the microbial and metabolite concentrations and their consistencies in kombucha across
production batches is necessary.

Funding

243 This study was supported by AMILI Pte. Ltd., Singapore.

Author Contributions

246 Conceptualization, GT, TKY and JL.; Methodology, JD, HSL, CCW, JLWJ; Writing – Original Draft

247 Preparation, JD, HSL.; Writing – Review & Editing, GT, TKY, JL, CCW, JD, HSL. All authors have read

248 and agreed to the published version of the manuscript.

Competing interests

251 SLH, KYT, GT are employees of AMILI Pte. Ltd. JWJL and JL are co-founders of AMILI Pte. Ltd. JD

252 and CWC declare no conflict of interests.

References

1. Jayabalan, R.; Malbaša, R.V.; Lončar, E.S.; Vitas, J.S.; Sathishkumar, M. A Review on

Kombucha Tea-Microbiology, Composition, Fermentation, Beneficial Effects, Toxicity, and Tea

Fungus. *Compr. Rev. Food Sci. Food Saf.* **2014**, *13*, 538-550, doi:10.1111/1541-4337.12073.

2. de Miranda, J.F.; Ruiz, L.F.; Silva, C.B.; Uekane, T.M.; Silva, K.A.; Gonzalez, A.G.M.;

Fernandes, F.F.; Lima, A.R. Kombucha: A review of substrates, regulations, composition, and

biological properties. *J. Food Sci.* **2022**, *87*, 503-527, doi:10.1111/1750-3841.16029.

3. Antolak, H.; Piechota, D.; Kucharska, A. Kombucha Tea-A Double Power of Bioactive

Compounds from Tea and Symbiotic Culture of Bacteria and Yeasts (SCOBY). *Antioxidants*

(Basel) **2021**, *10*, doi:10.3390/antiox10101541.

4. Villarreal-Soto, S. A.; Beaufort, S.; Bouajila, J.; Souchard, J.-P.; Taillandier, P. Understanding Kombucha Tea Fermentation: A Review. *J. Food Sci.* **2018**, *83* (3), 580–588, doi:10.1111/1750-3841.14068.

5. Qiu, X.; Zhang, Y.; Hong, H. Classification of Acetic Acid Bacteria and Their Acid Resistant Mechanism. *AMB Express* **2021**, *11* (1), doi:10.1186/s13568-021-01189-6.

6. Bishop, P.; Pitts, E. R.; Budner, D.; Thompson-Witrick, K. A. Kombucha: Biochemical and Microbiological Impacts on the Chemical and Flavor Profile. *Food Chem* **2022**, 100025, doi:10.1016/j.focha.2022.100025.

7. Harrison, K.; Curtin, C. Microbial Composition of SCOBY Starter Cultures Used by Commercial Kombucha Brewers in North America. *Microorganisms* **2021**, *9* (5), 1060, doi:10.3390/microorganisms9051060.

8. Yang, J.; Lagishetty, V.; Kurnia, P.; Henning, S.M.; Ahdoot, A.I.; Jacobs, J.P. Microbial and Chemical Profiles of Commercial Kombucha Products. *Nutrients* **2022**, *14*, 670, doi:10.3390/nu14030670.

9. Lavasani, P.S.; Motevaseli, E.; Sanikhani, N.S.; Modarressi, M.H. Komagataeibacter xylinus as a

novel probiotic candidate with high glucose conversion rate properties. *Heliyon* **2019**, *5*, e01571,

doi:10.1016/j.heliyon.2019.e01571.

10. Nguyen, N.K.; Dong, N.T.; Nguyen, H.T.; Le, P.H. Lactic acid bacteria: promising supplements

for enhancing the biological activities of kombucha. *Springerplus* **2015**, *4*, 91,

doi:10.1186/s40064-015-0872-3.

11. Mokoena, M. P. Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and

Applications against Uropathogens: A Mini-Review. *Molecules* **2017**, *22* (8), 1255,

doi:10.3390/molecules22081255.

12. Wang, Y.; Wu, J.; Lv, M.; Shao, Z.; Hungwe, M.; Wang, J.; Bai, X.; Xie, J.; Wang, Y.; Geng, W.

Metabolism Characteristics of Lactic Acid Bacteria and the Expanding Applications in Food

Industry. *Front. Bioeng. Biotechnol.* **2021**, *9,* doi:10.3389/fbioe.2021.612285.

13. McIver, L.J.; Abu-Ali, G.; Franzosa, E.A.; Schwager, R.; Morgan, X.C.; Waldron, L.; Segata, N.;

Huttenhower, C. bioBakery: a meta'omic analysis environment. *Bioinformatics* **2018**, *34*, 1235-

1237, doi: 10.1093/bioinformatics/btx754.

14. McMurdie, P.J.; Holmes, S. phyloseq: An R package for reproducible interactive analysis and

graphics of microbiome census data. *PLoS ONE* **2013**, *8*, e61217,

doi:10.1371/journal.pone.0061217.

15. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. Available online:

https://ggplot2.tidyverse.org (accessed on 10 March 2022).

16. Gu, Z.; Eils, R.; Schlesner, M. Complex Heatmaps Reveal Patterns and Correlations in

Multidimensional Genomic Data. *Bioinformatics (Oxford, England)* **2016**, *32* (18), 2847–2849,

doi:10.1093/bioinformatics/btw313.

17. Arikan, M.; Mitchell, A.L.; Finn, R.D.; Gurel, F. Microbial composition of Kombucha

determined using amplicon sequencing and shotgun metagenomics. *J. Food Sci.* **2020**, *85*, 455-

464, doi:10.1111/1750-3841.14992.

18. Kaashyap, M.; Cohen, M.; Mantri, N. Microbial Diversity and Characteristics of Kombucha as

Revealed by Metagenomic and Physicochemical Analysis. *Nutrients* **2021**, *13*,

doi:10.3390/nu13124446.

19. Zhao, Z.; Sui, Y.; Wu, H.; Zhou, C.; Hu, X.; Zhang, J. Flavour Chemical Dynamics During

Fermentation of Kombucha Tea. *Emir. J. Food Agric.* **2018**, *30*, 732-741,

doi:10.9755/ejfa.2018.v30.i9.1794.

20. Su, F.; Xu, P. Genomic Analysis of Thermophilic Bacillus Coagulans Strains: Efficient Producers
    for Platform Bio-Chemicals. *Sci. Rep* **2014**, *4*, 3926, doi:10.1038/srep03926.

21. Cao, J.; Yu, Z.; Liu, W.; Zhao, J.; Zhang, H.; Zhai, Q.; Chen, W. Probiotic characteristics of
    Bacillus coagulans and associated implications for human health and diseases. *J. Funct. Foods*
    2020, *64*, 103643, doi:10.1016/j.jff.2019.103643.

22. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A. N.; Mackay, C. R.; Macia, L. The Role of
    Short-Chain Fatty Acids in Health and Disease. *Adv. Immunol.* **2014**, 91–119, doi:10.1016/b978-
    0-12-800100-4.00003-9.

23. Schönfeld, P.; Wojtczak, L. Short- and Medium-Chain Fatty Acids in Energy Metabolism: The
    Cellular Perspective. *J Lipid Res*. **2016**, *57* (6), 943–954, doi:10.1194/jlr.R067629.

24. PubChem. Fatty Acid Oxidation. Available online:
    https://pubchem.ncbi.nlm.nih.gov/pathway/PathBank:SMP0000781 (accessed on 25 May 2022).